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Abstract
Background: Telomere/telomerase system has been recently recognized as an attractive target for anticancer therapy.
Telomerase inhibition results in tumor regression and increased sensitivity to various cytotoxic drugs. However, it has not
been fully established yet whether the mediator of these effects is telomerase inhibition per se or telomere shortening
resulting from inhibition of telomerase activity. In addition, the characteristics and mechanisms of sensitization to cytotoxic
drugs caused by telomerase inhibition has not been elucidated in a systematic manner.
Methodology/Principal Findings: In this study we characterized the relative importance of telomerase inhibition versus
telomere shortening in cancer cells. Sensitization of cancer cells to cytotoxic drugs was achieved by telomere shortening in
a length dependent manner and not by telomerase inhibition per se. In our system this sensitization was related to the
mechanism of action of the cytotoxic drug. In addition, telomere shortening affected also other cancer cell functions such as
migration. Telomere shortening induced DNA damage whose repair was impaired after administration of cisplatinum while
doxorubicin or vincristine did not affect the DNA repair. These findings were verified also in in vivo mouse model. The
putative explanation underlying the phenotype induced by telomere shortening may be related to changes in expression of
various microRNAs triggered by telomere shortening.
Conclusions/Significance: To our best knowledge this is the first study characterizing the relative impact of telomerase
inhibition and telomere shortening on several aspects of cancer cell phenotype, especially related to sensitivity to cytotoxic
drugs and its putative mechanisms. The microRNA changes in cancer cells upon telomere shortening are novel information.
These findings may facilitate the development of telomere based approaches in treatment of cancer.
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Introduction
Human telomeres are composed of single stranded TTAGGG
repeats and corresponding duplexes of this hexanucleotide located
at both ends of the linear chromosome. Together with their
specific shelterin protein complex they provide stability to the
whole genome, by masking chromosome ends from being
treated by DNA repair mechanisms as double strand breaks [1].
Telomeres incrementally erode in most somatic cells upon each
round of DNA replication, until they reach critical short length
which eventually initiates a cessation of cell growth termed
cellular senescence [2]. Cancer cells use the enzyme telomerase
to circumvent telomere shortening, and thus achieve endless
replicative potential. Telomerase is a unique reverse trans-
criptase ribonucleoprotein complex that maintains a steady state
of telomere length by synthesizing TTAGGG repeats at the ends
of chromosomes. It is highly active in more than 90% of all
malignancies, and therefore considered a hallmark of cancer [3].
Telomerase is not expressed in most normal somatic cells but
retains moderate activity in proliferative stem cells and to a
higher extent in male germ line cells. Due to this specificity and
essentiality to the limitless lifespan of cancer cells, telomerase is
considered a valid and attractive anticancer target [4].
Indeed, numerous studies have shown that telomerase inhibi-
tion results in apoptosis of cancer cells, shrinkage of tumors in
experimental animal models and enhanced sensitivity of tumor
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whether these ’’beneficial biologically desirable’’ effects are the
consequence of telomere shortening or telomerase inhibition per se.
In addition, it has not been determined yet if the enhancement of
sensitivity to cytotoxic drugs by telomerase inhibition/telomere
shortening is dependent on the mechanism or class of the
chemotherapeutic agent.
Most of the data point to shortening of telomeres below a
critical limit as the most important target achieved by telomerase
inhibition [6,7], supporting the notion by which achievement of
significant telomere shortening will result in anti cancer clinical
effects. However, several studies implicate additional ‘‘extracur-
ricular’’ activities of telomerase which are independent of telomere
length regulation. For example, telomerase has been shown to
possess antiapoptotic properties [8,9]. In addition, its involvement
in DNA damage response [10] or DNA protection by ‘‘capping’’
[11] was determined as well. Telomerase was also implicated in
gene expression control irrespectively of telomere length and in
contribution to growth of various types of benign [12–14] and
malignant [15,16] cells.
The aim of this study was to clarify the importance of
telomerase inhibition per se versus the effect of telomere shortening
in cancer cells and to evaluate the effect of these perturbations on
the sensitivity of the cells to various cytotoxic drugs with different
mechanisms of action. In addition, we aimed at depicting the
mechanisms by which cells with shortened telomere length exhibit
differential sensitivity to these drugs.
We have found that telomerase inhibition per se does not alter
the sensitivity of several malignant cell lines to any of the drugs
tested. Long term telomerase inhibition which resulted in telomere
shortening sensitized the cells to cisplatinum, a DNA adducts
forming agent and not to doxorubicin, a double strand breaks
producing agent or to vincristine, which mode of action is not
through direct DNA damage. These results were confirmed in an
animal model employing nude mice with xenografts of pancreatic
carcinoma cells which were exposed to telomerase inhibitor and
cytotoxic drugs. Cells with shorter telomeres acquired DNA
damage phenotype whose repair was impaired after cisplatinum
only and expressed miRNA that are associated with growth arrest
of cancer cells. These cells also presented slower migration
compared to their wild type (WT) counterparts. We suggest that
telomere shortening in cancer cells is associated with changes in
miRNA expression and leads to impaired DNA repair after
exposure to cisplatinum specifically.
Materials and Methods
Cell Lines
SK-N-MC (Ewing sarcoma) cell line was kindly provided by Dr
Gad Lavie (Sheba Medical Center, Ramat-Gan, Israel). MCF-7
(breast carcinoma) and K562 (chronic myeloid leukemia) cells
were maintained in RPMI 1640 supplemented with 10–15% heat-
inactivated fetal calf serum (FCS), glutamine (2 mM), penicillin
and streptomycin (Beit Haemek, Israel). Proliferation assays,
apoptosis analyses and telomerase activity assays were performed
on all cell lines. SK-N-MC line was chosen for further detailed
analysis of various mechanisms related to the effect of telomerase
inhibition on sensitivity to cisplatinum. The control cells were
maintained in culture without telomerase inhibitor, GRN163, in
parallel with the telomerase inhibited cells.
Telomerase Inhibition
Cells were exposed twice a week to telomerase inhibitor
GRN163, targeting the template region of RNA subunit of
telomerase (hTR). The control cells were maintained in culture
without telomerase inhibitor in parallel with the inhibited cells. For
the in vivo inhibition of telomerase, mice were injected with
GRN163L, a palmitoyl (C16) lipid-attached N39-P59 phosphor-
amidate version of GRN163. Both compounds were kindly
provided by Geron Corporation (Menlo Park, CA, USA)
Drug Treatment and In Vitro Experimental Protocol
All cell lines were exposed to the following drugs for three days
prior to the proliferation, cell cycle and apoptosis analyses:
Cisplatinum, a DNA adducts forming drug, doxorubicin, a double
strand breaking agent and vincristine, which interferes with the
formation of spindle microtubules, thus stops the separation of the
duplicated chromosomes and prevents cell division. Concentration
of the drugs is depicted in the results section.
To assess the effect of telomerase inhibition versus telomere
shortening on the sensitivity of the cells to the cytotoxic drugs we
devised four experimental conditions: 1. Telomerase was inhibited
in the three cell lines for three days creating cells without
telomerase activity and with intact (WT) telomeres. 2. Long term
inhibition (from three to 16 months), creating cells without
telomerase activity and shortened telomeres. 3. Withdrawal of the
telomerase inhibitor in cells with shortened telomeres, creating
cells with short telomeres and reconstituted telomerase activity. 4.
As a control we used intact wild type cells. Telomere length and
the IC50 of the three cytotoxic drugs were determined after 3 and




21 SK-N-MC and MCF-7) were
seeded in quadruplicate in 24-well plates. Various drugs were
added at the following concentrations range: vincristine: 0–
100 ng/ml, doxorubicin: 0–1000 ng/ml and cisplatinum: 0–
10 mg/ml. After 3 days, proliferation was determined with the
sulphorhodamine B assay [17]. The proliferation of the non-
adherent K562 cells was determined by the WST-1 assay which
follows the conversion of tetrazolium salt into formazan dye by
mitochondrial enzymes according to the manufacturer’s instruc-
tions (Roche, Germany) and as described previously [17].
TRAP Assay
Cells (5610
4/ml) were plated in 24-well plates and incubated in
the presence of GRN163 for 1–3 days. Each treatment was
performed in duplicates. Subsequently, measurement of telome-
rase activity was performed by the PCR-based TRAP assay, using
the TRAPEZE telomerase detection kit (Intergene, NY, USA),
according to the manufacturer’s instructions and as previously
described [17]. Briefly, cells were lysed with ice-cold CHAPS lysis
buffer) for 30 min at 4uC and were subsequently centrifuged at
13,000 rpm for 30 min at 4uC. The supernatant was then
collected and the protein concentration was determined by the
Bradford assay (Bio-Rad Laboratories, CA, USA). Protein extracts
(0.2 mg) were assayed for TRAP analysis. Each reaction was
performed in a 50 ml reaction mixture containing 106TRAP
buffer, dNTP mix, TS primer, TRAP primer mix and Taq
polymerase. Reactions were performed at 30uC for 30 min and
were then subjected to PCR amplification for 30 cycles of 94uC,
58uC and 72uC for 30 s each, and were separated by
electrophoresis on 12.5% polyacrylamide gels (Acryl/Bis 19:1
solution). Gels were stained with SYBER Green nucleic acid gel
stain (Amresco, Ohio, USA). Quantifications were performed
using the Quantity-one software for Bio-Rad’s Image analysis
systems (Bio-Rad Laboratories, Israel). Telomerase activity was
calculated according to the following formula: TPG=[(X2X0)/
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signifies each sample, C represents the 36 bp internal PCR
control, r is the TSR8 quantification control.
TRF Length
Terminal restriction fragment (TRF) length, corresponding to
telomere length, was measured by a non-radioactive Southern blot
technique. DNA samples were extracted from the cells by the
Genomic DNA purification kit (Gentra, Minneapolis, MN, USA)
according to the manufacturer’s instructions, digested for 16 h by
HinfIII and RSAI and separated on 0?8% agarose gels. After
transfer to positively charged nylon membrane, samples were
hybridized with digoxigenin-labelled probe (TTAGGG)4 (Roche
Applied Science, Mannheim, Germany) for 16–18 h. The
membranes were then exposed to chemiluminescence-sensitive
films, and the average TRF lengths were calculated by the Versa
Doc Imaging System, using Quantity One software (Bio-Rad
Laboratories).
Analyses of miR Signature
RNA isolation. RNA was isolated by using the EZ-RNA II
commercial kit (Biological Industries, Beit Haemek, Israel)
according to the manufacturer’s instructions provided. In
general, cells after relevant treatments were lysed in lysis buffer
of the kit and stored at 270uC prior to RNA extraction which was
done to all cells at once, prior to hybridization with the miRNA
arrays.
MicroRNA microarray. Custom microRNA microarrays
have been described previously [18]. Briefly, ,900 DNA
Oligonucleotide probes representing microRNA (Sanger
database version 10 and additional microRNAs predicted and
validated by Rosetta Genomics) were spotted in triplicates on
coated microarray slides (NexterionH Slide E. Schott, Mainz,
Germany). Each RNA sample (15 mg of total RNA) was labeled by
ligation of an RNA-linker, p-rCru-Cy/Dye (Dharmacon
Lafayette, CO: Cy3 or Cy5) to the 39 end. Slides were
incubated with the labeled RNA for 12–16 hours at 42uC and
then washed twice. Arrays were scanned at resolution of 10 mm
and images were analyzed using SpotReader software (Niles
Scientific Portola Valley, CA). Two types of positive controls were
included in the experimental design: (i) synthetic small RNAs were
spiked into each RNA sample before labeling to verify labeling
efficiency and (ii) probes for abundant small RNAs were spotted to
validate RNA quality. Microarray spots were combined and
signals normalized as described previously [18].
Data analysis. The data included two samples: SK-N-MC
cells with intact telomeres and SK-N-MC cells with shortened
telomeres. A total of 170 microRNA probes had a signal that
passed the minimal threshold of 300 in at least one of the samples.
For each of those microRNA molecules we calculated the signal
fold change between the samples with short telomeres and the
sample with intact telomeres.
Cell Cycle and Apoptosis Analyses
Cells (0.7–1610
4 ml
21) were cultured for 3 days. Floating and
adherent cells were combined, washed with PBS and nuclei
prepared from 5610
5 to 1610
6 cells for flow cytometric analysis
using a detergent-trypsin method followed by staining with
propidium iodide [19]. DNA content was analyzed by FACSCA-
LIBUR (Becton Dickinson, San Jose, CA, USA), using ModFitLT
cell cycle analysis software (Verity Software House Inc., Topsham,
ME, USA). Apoptosis was assessed by FACS analysis by which
cells in the pre-G1 stage of the cell cycle were defined as apoptotic.
Detection of cH2AX Foci
Cells were plated on cover slides and exposed to the drugs for
24h, fixed and processed as previously described [20]. Briefly, cells
were fixed with 4% paraformaldehide, washed three times with
PBS, and permeabilized with 5% Triton X for 10 min. After three
washes with PBS, cells were blocked by 10% normal donkey serum
and 1% BSA, washed again with PBS and incubated with cH2AX
antibody solution (1:350, Upstate Biotechnology, NY, USA) for
16h at 4uC. The second antibody CY2 conjugated anti mouse
(Jackson Immuno Research Laboratories, PA, USA) was added
after three washed with PBS. Cover slides were stained with DAPI
and mounting solution. cH2AX foci were visualized under the
fluorescent microscope (Applied Spectral Imaging, Migdal Hae-
mek, Israel). 50 nuclei were counted for each sample.
The Comet Assay
DNA damage levels in cells with different telomere lengths and
damages incurred after exposure to drugs were assessed by the
comet assay, as described [21]. This assay follows the fragility level
of the DNA by assessing DNA fragments migration (products of
single and/or double strand breaks) from nucleus core to form
comet shape when exposed to electrophoretic field. After staining
with ethidium bromide, the extent of the comet can be monitored
and quantified. Basically, cell suspension was mixed with 0.65%
low-melting agarose and spread on a Star-frost microscope slide,
pre-coated with 0.65% normal melting agarose. A third layer
containing 0.65% low-melting agarose was placed on top and the
cells were then lysed by immersing the slides overnight in a freshly
prepared lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM
Tris, 1% Triton X-100, 10% DMSO, pH 10.0) at 4uC. After lysis,
the slides were washed three times in cold water and placed in a
horizontal gel electrophoresis apparatus containing freshly pre-
pared electrophoresis buffer (1 mM EDTA, 300 mM NaOH,
pH=13.0) for 20 min to allow DNA unwinding. Electrophoresis
was then carried out at 20 V and at a starting current of 300 mA
for 20 min at 4uC. Thereafter, the slides were neutralized with
three washes of 0.4 M Tris, pH=7.5, dehydrated with ethanol
and dried. The slides were stained with 20 mg/ml ethidium
bromide solution and viewed under a fluorescent illumination
using 530–550 nm excitation filter and 590 nm barrier filter (U-
MNG cube, Olympus, Germany). All steps were conducted in the
dark to prevent additional DNA damage. To evaluate comet
parameters, slides were examined in parallel using Viscomet image
analysis software. A total of 150 randomly chosen cells from
triplicate slides were examined for each sample (50 cells per slide).
Image analysis was performed at 6200 magnification. The cell
images were projected onto a high-resolution Heper-HAD
TM
(Sony, Japan) CCD camera (8 bits [Applitec, Israel, LIS-700]) and
analyzed with Viscomet image analysis software using the MV
Delta frame grabber (Matrix Vision, Germany). DNA damage was
measured using the following parameters: comet extent (the
distance from the leading head edge to the trailing edge of the tail),
percentage tail DNA (percentage of DNA in tail), and tail extent
moment (tail length X percentage tail DNA). Slides were coded
and a single investigator analyzed all slides to minimize scoring
variation.
Migration Assays
Migration of cells was evaluated by two assays: the wound
healing assay and a modified Boyden chamber assay (transwell
assay).
The wound healing assay was performed according to ref [22].
Cells were seeded at a density of 0.2610
6 cells/well in six-well
culture plates and allowed to form a confluent monolayer. The
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wound of ,1 mm width. Images of the wounds were captured at
t=0 and 24 h at 640 magnification and the wound area was
determined using the Scion Image for windows alpha 4.0.3.2
software. The ability of the cells to close the wound, that is,
their motility, was evaluated by determining the healed area.
Percentage of healed area was calculated in the following
way: (wound area at t=02wound area at t=22)/wound area
at t=0) 6100. The plates were marked to ensure consistent photo-
documentation.
The Modified Boyden chamber was performed as described
previously [23]. Cells were seeded in triplicates on polycarbonate
filters with 8 mm pores positioned on the upper compartment of
24-well transwell chambers (Costar, Cambridge, Mass, USA). The
bottom surface of the transwell chambers was coated with
fibronectin (5 mg/filter). Culture medium was added to the lower
compartment. The cells were allowed to migrate for 18 hours at
37uC and the filters were then fixed with methanol and stained
with Giemsa stain. The cells on the upper surface of the filter were
removed with a cotton swab. Finally, cells that have migrated to
the bottom side of the filter were photographed and counted under
a microscope.
Animals
Athymic female or male BALB/c nu/nu mice, 5–6 week old,
were purchased from Harlan Ltd. (Jerusalem, Israel). The mice
were housed under specific pathogen-free conditions in top filtered
cages and fed a regular diet. All procedures were conducted using
facilities and protocols approved by the Animal Care and Use
Committee of the Hadassah-Hebrew University School of
Medicine.
Human Xenograft Murine Model
CRL 1867 cells (human pancreas carcinoma) were harvested by
trypsinization of confluent cultures, washed, and resuspended at
1.0610
8 cells/ml in growth medium. Mice were inoculated with
CRL 1687 cells in 100ul medium under the dorsal skin one day
following whole body irradiation at 400 cGy, delivered by a linear
accelerator (Varian Climac 66) at a source to skin distance of
80 cm, and a dose rate of 170 cGy/min. Mice were treated with
30mg/kg i.p. GRN 163L 3 times per week for several weeks,
starting one day after tumor injection. The control group was
injected with PBS (0.2 ml i.p.). Tumor growth was monitored
every 6–8 days by caliper measurements of two perpendi-
cular diameters of xenografts (D1, the larger diameter and
D2, the smaller diameter). Tumor volume was measured using
the formula: p/6 (D16D2), and expressed as mean tumor volume
6 SE (in mm
3). At 41–55 days after cell injection, at the time of
killing, tumors were excised free of connective tissue, weighted and
half of them were frozen in liquid nitrogen. The other half
was used for telomere length determination and pathological
parameters.
Histology
At the end of the experiments, mice were sacrificed and the
tumor, pancreas, and lung tissue were removed. Tissues were fixed
in 10% formalin, embedded in paraffin, stained with hematoxylin
and eosin, and evaluated by light microscopy.
Results
In Vitro Studies
Telomerase inhibition with GRN163 shortens telomeres.
Administration of GRN163 resulted in 70–90% inhibition of
telomerase (Fig. 1a). This inhibition persisted up to 72 hours
and repeated measurements throughout the 16 months of the
experiment verified continuous inhibition of telomerase at this
range (not shown). In all cell lines the telomeres were shortened in a
range of 20–30% and 40% after 3 and 16 months, respectively
(Fig. 1 b).
Telomere shortening but no telomerase inhibition per se
sensitizes cells specifically to cisplatinum. As shown in
Fig. 2 and Table 1 telomere shortening increased the sensitivity of
the three cell lines to cisplatinum in a length dependent manner.
Telomerase inhibition per se had no independent effect on cells
sensitivity to cisplatinum. The IC50 of cisplatinum decreased from
0.13mg/ml to 0.07mg/ml after 16 months. Telomere shortening
did not affect significantly the cells’ sensitivity to doxorubicin and
vincristine. Table 1 summarizes these results and Fig. 2 shows in
details the changes in sensitivity of SK-N-MC cells to cisplatinum.
Since all cell lines behaved similarly in this respect, we selected
SK-N-MC cells as a model for further characterization of
the mechanisms underlying the telomere shortening induced
sensitization of cancer cells to chemotherapy and the differential
sensitivity to cisplatinum.
Telomere shortening does not affect the cell cycle status
after the exposure to cytotoxic drugs. Telomere shortening
did not affect the cell cycle status of the cells (bars A and C in
Fig. 2b). Exposure of the cells to cisplatinum resulted in decrease
of G0/G1 and increase of G2/M stages of the cell cycle. These
changes were not affected by the shortening of telomeres (fig. 2b).
Also, telomere shortening did increase the apoptotic rate of the
cells due to chemotherapy (Fig. 2c).
Telomere shortening slower the migration of cancer
cells. Since in vitro migration of cancer cells is considered a
valid representation of their metastatic potential, we evaluated the
effect of telomere shortening on this feature as well. The migration
was assessed by transwell membrane (Boyden chamber) (Fig. 3a, b)
and the wound healing (Fig. 3c, d) assays. As shown in Fig. 3, on
the transwell membrane assay the cells with shortened telomeres
migrated significantly slower than the control cells. The wound
healing assay also demonstrated tendency towards slower
migration, but the results did not reach statistical significance.
The subsequent studies were performed in order to elucidate the
potential mechanisms underlying the phenotypic changes induced
by telomere shortening.
Telomere shortening is associated with increased DNA
damage and impaired DNA repair ability as evaluated by
comet assay. Cisplatinum further impairs the DNA repair
in cells with shortened telomeres. Telomeres shortening
may enhance DNA damage response due to loss of its protective
function. To evaluate the level of the DNA damage in cells with
shorter telomeres, we employed the comet assay. As shown in
Fig. 4a, b telomere shortening was associated with DNA damage
in the cells. Tail extent moment parameter (reflecting tail length X
percentage tail DNA, while tail length is the distance in mm from
the head center to the end of the tail) was 30% higher in the cells
with shorter telomeres. Assessment of all other comet assay
parameters revealed similar results, and the overall comet intensity
increased in about 16% in these cells.
To understand why cells with shorter telomeres are more
sensitive to cisplatinum than to doxorubicin, the cells were exposed
to these drugs for one hour followed by changing the medium to
medium without drug. DNA damage levels were evaluated 2 and
4 hours post drug exposure using the comet assay. As shown in
Fig. 4c, both drugs induced DNA damage, but the cells with
shortened telomeres failed to repair the DNA damage caused by
cisplatinum, while the doxorubicin induced damage was repaired
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telomeres.
Telomere shortening is associated with formation of
telomere damage induced foci (TIF) whose repair is
impaired in cells with shortened telomeres. Cisplatinum
further impairs the clearance of TIFs following telomere
shortening. DNA damage response at telomeres is manifested
by appearance of TIF containing cH2AX. We followed the
formation of cH2AX foci in cells with shortened telomeres and
following treatment with cisplatinum or doxorubicin. Telomere
shortening resulted in the appearance of TIF. Administration of
cisplatinum or doxorubicin also caused TIF in cells with intact
telomeres and increased their number in cells with shortened
telomeres (Fig. 5a, b). We did not verify, however, whether these
TIF were associated with telomeres only, or were spread
throughout the genome.
TIF formation is an indicator of the DNA repair ability of the
cells. To assess this property of cells with shortened telomeres, we
followed the disappearance of TIF after withdrawal of the
cytotoxic drugs. In cells with shortened telomeres exposed to
cisplatinum the number of TIF did not change significantly up to
24h after the withdrawal of the drug from the growth medium
(Fig. 5a, b). In contrast, the number of TIF induced by
doxorubicin decreased by 50% after 24h in these cells, implying
that the damage induced by this drug does not impair the DNA
repair process in cells with shortened telomeres. Collectively, these
data may explain the differential sensitivity of cells with shorter
telomeres to cisplatinum, which probably stems from their inability
to cope with DNA adducts induced by cisplatinum versus DNA
double stranded breaks caused by doxorubicin.
Telomere shortening affects micro RNA expression.
The above mentioned phenotypic changes caused by telomere
shortening in cancer cells are probably caused by alterations in
gene expression. We decided to look at the changes in miRNA
expression as an initial step to study the genetic changes induced
by telomere shortening. We performed profiling of expression of
,900 micro RNA (miR) comparing SK-N-MC cells with intact
telomeres (about 7kb), shortened telomeres (about 4 kb) and cells
whose shortened telomeres were elongated back to their original
size (about 7 kb) by reconstitution of telomerase activity. While
cells with re-elongated telomeres exhibited similar pattern of miR
expression compared to the cells with intact telomere length, cells
with shortened telomeres demonstrated different profile of miR
expression. The complete list of the up and down regulated miRs
is beyond the scope of this paper and will be reported in another
publication. Interestingly, some of the miRs with differential
Figure 1. GRN163 inhibits telomerase activity in a sequence specific manner and shortens telomeres. a. SK-N-MC, MCF-7 and K562 were
exposed to 5uM of GRN163. Telomerase activity was assessed by the TRAP assay after 24hours. C- control untreated cells, M- mismatch nonspecific
scrambled oligo, I-telomerase inhibitor GRN163. R8- standard TRAP control, N- negative control with no cell extracts, IC- internal PCR control. The
extent of telomerase inhibition is denoted in percentages below the lanes. b. SK-N-MC cells were continuously exposed to 5mM of GRN163. Telomere
length was measured by Southern blot. C- control untreated cells, Ia- telomere length of cells exposed to telomerase inhibitor for three months, Ib-
telomere length of cells exposed to telomerase inhibitor for 16 months, M- molecular size marker. Mean telomere length is denoted below each lane,
and the percent of telomere shortening is shown as well. c. Graphical presentation of the extent of telomere shortening after the exposure of SK-N-
MC cells to GRN163 for 1 year as measured by Southern blot.
doi:10.1371/journal.pone.0009132.g001
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inhibition, apoptosis or malignant processes and may explain the
sensitization to cisplatinum and impaired migration (Table 2). The
table depicts several miRs that may have biological relevance to
the characteristic phenotype of cells with shortened telomeres
illustrated in our study. These differences in miR expression may
serve as a starting point to explore the genetic changes caused by
telomere shortening leading to the above described phenotype of
cancer cells.
In Vivo Studies
Telomerase inhibition by GRN163L does not prevent
implantation of CRL 1687 tumor but slows the tumor
growth. BALB/c nude mice were injected with CRL1687
cells (pancreatic adenocarcinoma) and treated with GRN163L, a
telomerase inhibitor, three times a week (30mg/kgBW) as
described previously [24]. We selected these specific cells for our
studies due to their excellent response to telomerase inhibitor
GRN163L (not shown), which was better than the response of 5
other cell line tested. Since telomere shortening induced drug
sensitivities in several cell lines, we assumed that using another
cancer cell line for the in vivo studies will not affect the results.
Three days telomerase inhibition in these cells did not affect their
implantation rate in the animals compared to cells with active
telomerase (not shown). Treatment with the telomerase inhibitor
resulted in decreased growth rate of the tumors (Fig. 6a). After 5
weeks the average tumor size in the control group, treated with
PBS, was 0.52660.055 cm
3, whereas the in the GRN163L treated
mice the tumors dimensions were 0.29960.045, cm
3 a statistically
significant difference.
The combined effect of cisplatinum or vincristine on
xenograft sizes with inhibited activity of telomerase. To
verify the in vitro results regarding the combined effect of
telomerase inhibition and chemotherapy, mice were treated with
either vincristine or cisplatinum after 5–7 weeks of telomerase
inhibition. Since tumor sizes varied between the groups due to the
inhibition of telomerase, we started the treatment after reaching
similar size of tumors at both groups. Accordingly, the control
(PBS treated) group was exposed to chemotherapy after 5 weeks
and the telomerase inhibited group was exposed to the drugs after
7 weeks. 0.4mg/kgBW vincristine was injected i.p. once a week
every week for 7 weeks and 3 mg/kgBW cisplatinum was applied
i.p. twice a week every two weeks. These concentrations were
calibrated prior to the experiment and were the highest doses that
did not harm the animals’ weight or their general well being (not
shown). Animals were sacrificed 7 weeks after the completion of
each treatment and tumor size was evaluated (Fig. 6b). Tumors
exposed to telomerase inhibitors were smaller than their control
counterparts (weight: 0.4960.31 vs. 0.5860.16 gr9 respectively,
size: 0.3360.24 vs. 0.6460.09 cm
3 respectively) with cisplatinum
being synergistic with telomere shortening. Telomere shortening
did not increase the efficacy of vincristine in terms of tumor
growth.
The effect of telomerase inhibition on telomere length in the
animals was evaluated after 5 weeks of administration of
GRN163L. Mice were sacrificed and the average length of their
tumor telomeres was evaluated by Southern blotting (Fig. 6c). In
all tumors, the average telomere length decreased by 50% (from
4.25 kb to 2.3kb). Interestingly, the in vivo telomere shortening was
much more rapid than that in vitro. The in vitro inhibition for 16
months achieved 40% telomere reduction while in vivo, 50%
reduction was obtained after 5 weeks only. Since the mice
telomeres were much longer (,50kb) from that of the tumor cells
(,4 kb), they did not interfere with the interpretation of the results
regarding telomere length of the treated tumors in vivo. Fig. 6 c
shows only the CRL1867 telomeres, while the mice telomeres are
not shown.
Histological parameters of xenografts from mice treated
with telomerase inhibitor and cytotoxic drugs. Telomere
Figure 2. Sensitivity of SK-N-MC cells to cisplatinum is
telomere length dependent. a. Proliferation of cells with shortened
telomeres exposed to cisplatinum. SK-N-MC cells were continuously
exposed to GRN163. The sensitivity of the cells to cisplatinum was
estimated after three and 16 months of telomerase inhibition. Numbers
indicate the IC50 of the drug in these time points (after 22% and 40%
reduction in telomere length). P value refers to difference between WT
and short tel-16 months. b. Cell cycle status of SK-N-MC cells with
shortened telomeres exposed to 0.13mg/ml cisplatinum. SK-N-MC cells
with shortened telomeres were exposed to cisplatinum and the cell
cycle status was evaluated by FACS. + or 2 refers to the exposure to
cisplatinum. C. The apoptotic index of SK-N-MC cells with shortened
telomeres exposed to cisplatinum. The same cells were analyzed by
FACS for their apoptotic index, as represented by their preG1 status.
The numbers indicate the LD50 of cisplatinum in cells with intact or
shortened telomeres.
doi:10.1371/journal.pone.0009132.g002
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The GRN163L treated tumor exhibited less tumor lymphatic
emboli, less foci of necrosis and tumor distance from epidermis as
the main features. All these findings suggest that telomere
shortening causes the tumor to acquire a less aggressive
phenotype. These histological findings are summarized in
Table 3 and shown in Fig. 7. The histological effects of
cisplatinum and vincristine administration were not as affected
as tumor kinetics by telomere shortening, probably due to the
considerable tissue damage exerted by the cytotoxic drugs per se.
Discussion
In this study we systematically addressed several questions
concerning the effect and mechanism of perturbations of the
telomere/telomerase system as a therapeutic modality in cancer
cells. The results of the study show that the most important goal in
this regard is significant telomere shortening. In spite of other
roles of telomerase in the cell it seems that chemosensitization of
cancer cells requires telomere shortening and telomerase
inhibition is a mean to achieve this end point. The features of
cells with shortened telomeres described in our paper were
obtained only after a significant (,40%) attrition of telomeres.
This conclusion is supported also by results of other studies using
different approaches and addressing different questions, all
related to the effect of telomere/telomerase perturbation on the
cancer cell. For example, shortening of telomeres by targeting
telomerase using various strategies caused inhibition of cancer
cells growth [25]. Cells isolated from mTERC
2/2 mice with
shortened telomeres were more sensitive to double strand breaks
forming drugs [10]. Likewise telomerase inhibition by small-
molecule (BIBR1532) sensitized drug-resistant and drug-sensitive
cells to chemotherapeutic treatment in a telomere length
dependent manner [26]. Similarly, shortening of telomeres
caused by siRNA to telomerase sensitized cancer cells to ionizing
radiation and chemotherapy [27]. Additionally, telomerase
inhibition enhanced the response to anticancer drug treatment
in human breast cancer cells [28]. Other studies have shown a
similar effect on various cancer cell lines [29–31]. Another report
pointed to telomere structure rather than its length as a cause of
increased susceptibility of tumor cells to anticancer drugs [32].
Several other studies, however, reached different conclusions by
showing that telomerase inhibition sensitized cancer cells to
cytotoxic treatment independently of telomere shortening
[33–35]. This was attributed to a capping protecting function of
telomerase on telomeres. The contribution of our study is the
systematic approach focusing on the effect of telomere shortening
versus telomerase inhibition. By creating an experimental system
which included cells with inhibited versus active telomerase (with
shortened and intact telomeres) we were able to show that
telomerase inhibition per se does not confer sensitivity to
chemotherapy in our experimental setting.
Table 1. Effects of telomerase inhibition and telomere shortening on the sensitivity of cancer cells to cytotoxic drugs.
Telomere length TA SK-N-MC
IC50 of Vincristine (ng/ml) IC50 of Doxorubicin ng/ml IC50 of Cisplatinum ug/ml
Intact telomeres + 8 49 0.13
2 8 50 0.13
Shortened telomeres ,75% of the original size + 8.3 50 0.11
2 8 49 0.11
,60% of the original size + 7.9 49 0.07*
2 7.85 49 0.07*
Telomere length TA K562
IC50 of Vincristine (ng/ml) IC50 of Doxorubicin ng/ml IC50 of Cisplatinum ug/ml
Intact telomeres + 12 125 3.02
2 12 125 3
Shortened telomeres ,75% of the original size + 13 125 2.1
2 13 125 2.1
,60% of the original size + 12 123 1.7*
2 12.5 124 1.65*
Telomere length TA MCF-7
IC50 of Vincristine (ng/ml) IC50 of Doxorubicin ng/ml IC50 of Cisplatinum ug/ml
Intact telomeres + 10 250 3
2 10 250 3
Shortened telomeres ,75% of the original size + 10 250 2.5
2 10 250 2.5
,60% of the original size + 9.8 250 1.6*
2 10 250 1.6*
*- significance of P,0.05.
TA- telomerase activity.
doi:10.1371/journal.pone.0009132.t001
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we have used selected representatives of malignant cells:
mesenchymal cells (SK-N-MC), hematological malignant cells
(K-562) and epithelial cells (MCF-7). All cells reacted similarly in
terms of drug sensitivity after telomere shortening; therefore we
speculated that the sensitivity of cells with shortened telomeres can
be regarded a general phenomenon common to the majority of
malignant cells. Therefore we continued the further studies on one
cell line only.
This study demonstrates that the synergism between telomere
shortening and exposure to cytotoxic drugs is related to the
mechanism of action of these drugs. Telomere shortening resulted
in increased sensitivity only to cisplatinum, while the IC50 of
doxorubicin and vincristine did not change. We obtained similar
results in three different types of cancer cells. However, we cannot
conclude that this is a general phenomenon, since other groups
reported that telomere shortening sensitisized normal and
neoplastic cells derived from telomerase RNA null mice to
doxorubicin [10]. Another study showed that shortening of
telomeres in breast cancer cells sensitized these cells to cytotoxic
drugs regardless of their mechanism of action [28]. These differing
results may stem from different biological characteristics such as
damage response pathways in various tumor cells, which
according to the results of this study, may be the main venue of
chemosensitization [36].
The particular association between telomere/telomerase and
cisplatinum is not surprising in view of the reported effects of
cisplatinum on this system [37]. Cisplatinum has been shown to
associate specifically with the G-rich telomere strand [37] and also
inhibited telomerase activity in numerous types of cancer cells [e.g.
ref 38]. These findings, however, do not explain the mechanism of
sensitization demonstrated in our study. Therefore, we attempted
to explore the possible mechanisms of this differential sensitization.
The results point to impairment of specific types of DNA damage
repair that may be affected by telomere shortening. As there are
no apparent common structural features among doxorubicin
mediated DNA lesions and the 1,2- and 1,3-diguanyl DNA
intrastrand crosslinks, which are the major cisplatinum DNA
adducts [39], their repair could be exerted by different
mechanisms. Doxorubicin induces single- and double-strand
breaks in DNA resulting from its binding to the DNA and
blocking its unwinding and helicase activities, leading to inhibition
of replication and transcription. This damage is repaired mainly
by homologous recombination via the mismatch repair pathway
through a mechanism distinct from the manner by which covalent
DNA lesions produced by cisplatinum are processed [40]. This
pathway is probably intact or less affected in telomere shortened
phenotype. In contrast, DNA repair of single strand damage
formed by cisplatinum exerted by the general nucleotide excision
repair pathway, which differs from the mismatch repair pathway
Figure 3. The migration ability of cells with shortened telomeres. The migration of cells with shortened telomeres was evaluated by the
transwell and the wound healing assays. a. The transwell membrane assay. Cells with intact or shortened telomeres were allowed to migrate through
a membrane for 16 hours, Gimza stained and counted. A representative picture is shown. b. Graphical demonstration of the average cell counts of
four independent experiments. c. The wound healing assay. Cells with shortened telomeres were plated on Petri dishes, and the culture was
‘‘scratched’’ and followed for 24 hours. Average measurements of the cell free gaps were done. A representative example is shown. d. Graphical
demonstration of the average cell counts of four independent experiments.
doi:10.1371/journal.pone.0009132.g003
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Cells nuclei were exposed to electrophoresis and stained with ethidium bromide. Broken DNA migrates out of the nuclei and forms the comet. Three
degrees of DNA damage are shown: control nuclei with intact DNA (representing DNA damage in cells with intact telomeres, #1), intermediate state
in cells with partially broken DNA (representing cells with mild telomere shortening, #2) and cells with shortened telomeres harboring damaged
broken DNA (representing cells with shortened telomeres, #3). b. Quantitation of the extent of the DNA damage status of cells with shortened
telomeres, performed by screening 50 images per sample in quadruples. On the left- Tail extent moment parameter, on the right- total comet
intensities. c. Quantitation of the extent of the ability of the cells to repair DNA damage applied by doxorubicin (right panel) or cisplatinum (left
panel) 2 and 4 hours post drug induced damage. The assay was performed by screening 50 images per sample in quadruples. The DNA damage
status was determined by calculating the tail extent moment.
doi:10.1371/journal.pone.0009132.g004
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or slowed with telomere shortening. These results may explain also
the fact that the effect of vincristine, which does not damage DNA
directly, is not affected at all by the shortening of telomeres. The
findings of this study suggest that DNA damage triggered by
telomere shortening is accentuated further by administration of
cisplatinum and doxorubicin. However, whereas doxorubicin
damage is repaired relatively well both in wild type and shortened
telomeres, the DNA damage repair after cisplatinum is impaired
by telomere shortening. The precise mechanisms of this
phenomenon should be further explored.
An interesting connection between the ability of cells to repair
DNA adducts and cellular or organism age was recently
reported [42]. Incubation of mononuclear cells with cisplatinum
induced DNA damage which were repaired faster in younger
people compared to older ones [42]. As severe telomere
shortening is one of the main mechanisms associated with
senescence, it is reasonable to assume that cancer cells with
shortened telomeres may have acquired several aspects of aged
cells, among them the inability to repair DNA damage induced
by cisplatinum.
These in vitro findings were demonstrated also in in vivo setting.
Telomere shortening slowed the growth rate of tumor xenografts
and verified the sensitization of the cells to cisplatinum. Moreover,
telomerase inhibition affected not only the growth kinetics of the
tumor, but also the biological characteristics as exemplified by the
pathological evaluation. The histological findings showed that
shortening of telomeres leads to a less aggressive phenotype of the
tumor. These results are in concert with studies of Dikmen
and Gryaznov [43] which reported similar histological finding
after telomerase inhibition. The animal model part of our study
revealed two other interesting findings. First, telomerase activity is
not essential to the implantation of the tumor. It is important,
though, to its further propagation which may stem from the fact
that at the time of tumor inoculation the telomere length was
still unaffected. This finding is in accordance with other studies,
suggesting that initial tumor formation can occur in the absence of
telomerase. Telomerase activity, however, is essential for tumor
maintenance [44]. Second, in vivo telomerase inhibition results in
much more rapid telomere shortening than that achieved in vitro.
This finding may have clinical implications in future human
studies of telomerase inhibitors.
Figure 5. The formation of cH2AX foci in cells with shortened telomeres. SK-N-MC cells were exposed to cisplatinum or doxorubicin for
1 hour and then resuspended in drug free medium. The formation of cH2AX foci was followed by immunofluorescence at the indicated time points
after the releasing from the drugs. Blue color indicates nuclei stained with DAPI, green foci were detected using cy2-labeled anti cH2AX antibody. A-
A representative example. B- Quantitation of the number of foci per sample. Averages were calculated for at least 50 nuclei were counted for each
duplicated sample and two experiments which yielded similar results.
doi:10.1371/journal.pone.0009132.g005
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another feature of the cancer cell; its migratory potential. The
migration assay is considered to reflect the metastatic potential of
the cell. These results are in accordance with the report showing
that telomere shortening resulting from rybozyme mediated
suppression of mouse mTR significantly reduced the invasiveness
and the metastatic potential of melanoma cells [45]. The same
effect was demonstrated by another study in which hTERT-
targeted RNA interference inhibited the tumorigenicity and
motility of HCT116 cells [46].
It is plausible that the above mentioned findings are caused by
genomic alterations triggered by telomere shortening. As an initial
step towards characterization of these changes we evaluated the
miRNA profile of the native versus telomere shortened cells. To
our best knowledge, this approach has not been reported yet in a
similar experimental setting. The profiling yielded distinct changes
in expression of several miRNA. Some of them, which were
upregulated in cells with shortened telomeres are more obvious
candidates, such as miR-199a, miR-Let7a-d that are related to
apoptotic or growth suppression processes (e.g. ref [47], and [48]
respectively). Additionally, oncogene suppressors such as miR-
181a,b [49], miR-148 [50], miR-143 [51], were highly expressed
in these cells as well. miRs that are related to growth and
proliferation were upregulated in cells with intact telomere length,
including miR-21 [52], miR-146b-5p [53], miR-18a, miR-19a
and miR-17, belonging to the 17-92 miR cluster [54], and miR-
125a [55]. Additional data from our laboratory (not shown) found
highly significant (p=0.0014) overlap between some of these miR
targets and proteins associated with sensitivity to cisplatinum. We
are currently in the process of further studies attempting to
determine the miRNAs and proteins with the most significant
functions contributing to the biological phenotype of ‘‘shortened
telomere’’ cancer cell.
Several studies found different miR expression in various
experimental systems which confer resistance or sensitivity to
cisplatinum. For example, exposure of ovarian cancer cells to
cisplatinum resulted in the upregulation of miR-23b, miR-381,
miR-340, and the downregulation of miR-520, miR-331, miR-
185 and miR-106a [56]. The targets of these miRs overlapped
with known proteins involved in cisplatinum resistance [56]. In
MCF-7 cells, upregulation of miR-21 (which was upregulated in
our shortened telomere cells) following dicer knockdown
enhanced sensitivity to cisplatinum [57]. Mir-372 and miR-
373 were reported as relevant to the response to cisplatinum in
human testis cancer cell lines [58]. Let-7i (a member of Let 7
family of miRs that were upregulated in cells with shortened
telomeres) was reported to significantly increase the resistance
of ovarian and breast cancer cells to cisplatinum [59]. Another
Table 2. miRs that were differentially expressed in cells with shorter telomeres.
miR symbol Fold change (WT/short tel signal) Putative relevance to the phenotype of cells with shorter telomeres
Upregulated in cells with shortened telomeres
hsa-let-7a 0.152 Possess anti growth effects in cancer cells in vitro (lung cancer, melanoma)




hsa-miR-128 0.1571 May be involved in Alzheimer pathology, or in ageing process in general
hsa-miR-138 0.0793 Targets telomerase, is downregulated in squamous cell carcinoma of the
tongue, anaplastic thyroid carcinoma and papillary thyroid carcinoma
hsa-miR-143 0.157 A tumor suppressor mir. Targets ERK5 and may potentially target kRas
hsa-miR-148a 0.1156 A tumor suppressor gene. Targets human DNMT3b protein, resulting in growth suppression.
hsa-miR-181a 0.1362 Targets oncogenes such as: the oncogenes 70-kD zeta-associated protein and Tcl1 in CLL
hsa-miR-181b 0.0709
hsa-miR-193a-3p 0.0848 A pro apoptotic miR, activates the caspase cascade.
hsa-miR-199a-3p 0.0684 a pro-apoptotic agent, targets MET and ERK2 proto-oncogenes.
hsa-miR-199a-5p 0.0077
Upregulated in cells with intact telomeres
hsa-miR-125a-5p 3.8808 Was upregulated in serous ovarian carcinoma and neuroblastoma,
implicated in proliferation and migration processes
hsa-miR-140-3p 3.5167 Is involved in cell growth in lung carcinoma cells, targets histone
deacetylase 4 which binds 53bp1 and involved in DNA repair
hsa-miR-146b-5p 9.3262 Is associated with inflammatory processes, is induced by NF-kappa B.
hsa-miR-17 5.9754 miRs 17, 18a and 19a belong to the 17-92 cluster which is associated with processes
related to proliferation and aggressiveness of malignancies and defined as pro-tumorigenic.
hsa-miR-18a 8.9537
hsa-miR-19a 7.0316
hsa-miR-192 3.0604 Its expression activates the survivin promoter in lung A549 cells,
regulates cancer cell growth. Targets SIP1.
hsa-miR-21 11.5308 Targets sprouty2 and promotes cellular outgrowths and carcinogenesis.
It targets tumor suppressor genes in invasion and metastasis.
doi:10.1371/journal.pone.0009132.t002
Telomere Shortening in Cancer
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9132study demonstrated that let-7e,m i R - 3 0 c ,m i R - 1 2 5 b ,m i R - 1 3 0 a
and miR-335 were always diversely expressed in ovarian cancer
cells resistant to cisplatinum [60]. Of these, the expression of
miR-125b changed significantly in our system. In addition,
miR-214 induced cell survival and cisplatinum resistance in
ovarian cell carcinoma [61]. miR-98 was implicated in con-
ferring resistance to cisplatinum in head and neck squa-
mous cell carcinoma [62]. The diversity of this data suggests
that miR signature can contain common as well as different
components depending on the cell line and experimental
conditions used.
The results of this study are relevant to the SKNMC cells, as
other cancer cells may present different features. However, the
similar effects of telomere shortening in three different cell lines
suggest that the results of our study may be relevant to a wide
array of cancer types.
These findings contribute to our knowledge concerning the
optimal conditions for interventions in telomere/telomerase axis
Figure 6. Tumor dimensions after the inhibition of telomerase. CRL 1687cells were injected subcutaneously to nude athymic mice, which
were treated three times a week with telomerase inhibitor, GRN163L or with PBS as a control. a. Average tumor sizes of the two groups of mice (each
contained 18 mice) which were measured every week. b. Each group of mice was subsequently divided into three subgroups: one treated with PBS or
GRN163L only, the other treated with doxorubicin and PBS or GRN163L, and a group treated with vincristine and PBS or GRN163L. The sizes of
xenografts were measure each week. c. In vivo telomere shortening after GRN163L administration. Nude athymic mice were injected with CRL1687
cells subcutaneously and treated with telomerase inhibitor, GRN163L, or PBS. Telomere length was evaluated by Southern blot. M- molecular size
marker (sizes are listed on the left). Numbers below the gel indicate average telomere length in KB and the extent of telomere shortening. 5 samples
of each cell type were analyzed. D. Graphical representation of telomere shortening in vivo after telomerase inhibition with GRN163L. TRF- terminal
repeats fragment indicated the length of telomeres. The telomeres shortened by ,40% after telomerase inhibition. The experiment was repeated
twice with 5 samples of each cell types.
doi:10.1371/journal.pone.0009132.g006
Table 3. Histological analyses of tumors with shortened telomeres.
Overall impression Invasion to lymphatic vessels Atypical mitoses Invasion to epidermis Ischemic necrosis and ulcer treatment
Very aggressive ++ ++ ++ ++ PBS
Non aggressive 22 2 2 GRN163L
N ++ denotes high frequent distribution of the described feature.
N 2 denotes no detection of the described feature.
doi:10.1371/journal.pone.0009132.t003
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such conditions is important for establishment of future therapeu-
tic schedules.
In summary, in this study we partially characterized the
conditions and mechanisms by which telomerase inhibition affects
cancer cells. Future studies will be focused at the molecular and
genetic changes caused by telomere shortening. Inducing these
changes will enable us to produce the ‘‘vulnerable’’ phenotype
without the long lag period required for telomere shortening
caused by telomerase inhibition.
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